Corporate News

• 
  Beilu Pharmaceutical Jiuwei Zhenxin granule was selected into the Quotscience and Technology Innovation Chinaquot New Drug Achievement

  2021/11/30

  Recently, Beilu Pharmaceutical Jiuwei Zhenxin Granules were successfully selected into the "Science and Innovation China" New Drug Achievement Case Library of the China Association for Scien...

  VIEW_MORE
• 
  Beilu was awarded the “Top 100 Small and Medium-sized Private Enterprises in Beijing” and “Top 100 Private Enterprises in Beijing for Social Responsibility”

  2021/09/17

  Recently, the Beijing Municipal Federation of Industry and Commerce and the Beijing Branch of China Construction Bank jointly held the“2021 Beijing Top 100 Private Enterprises Press Conference”.

  VIEW_MORE
• 
  Beilu's Gadopentetate Dimeglumine Injection Passed the Quality and Efficacy of Generic Drugs Consistency Evaluation

  2021/07/27

  Recently, our company received the“Drug Supplementary Application Approval Notice”(Notice Number: 2021B02267, 2021B02268) for two specifications of Gadopentetate Dimeglumine Injection.

  VIEW_MORE
• 
  Beilu Pharma's Iohexol Injection Won the Bid in the Fifth round of National Centralized Drug Procurement

  2021/06/24

  Beilu Pharma participated in the fifth round of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use of the Joint Procurement Office.

  VIEW_MORE
• 
  Congratulations: Beilu Pharma's Iodixanol Injection Passed the Consistency Evaluation for Generic Drugs

  2021/05/18

  Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA) on Iodixanol Injection.

  VIEW_MORE
• 
  Congratulations: Beilu Pharma's Iohexol Injection Passed the Consistency Evaluation for Generic Drugs

  2021/04/21

  Recently, Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA).

  VIEW_MORE
• 
  Good News: Beilu Pharmaceutical won the 2020 National Adverse Drug Reactions Monitoring and Evaluation Excellent Unit

  2021/04/12

  On March 11th, the National Medical Products Administration (NMPA) issued the “Notice Recognizing Excellent Units in the National Adverse Drug Reactions Monitoring and Evaluation 2020”.

  VIEW_MORE